Exploring an interesting dual functionality of anacardic acid for efficient paclitaxel delivery in breast cancer therapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Journo-Gershfeld G, Kapp D, Shamay Y, Kopeček J, David A. Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm. Res. 29(4), 1121–1133 (2012).
  Medline CASGoogle Scholar
• 2 Onetto N, Canetta R, Winograd B et al. Overview of taxol safety. J. Natl Cancer Inst. Monogr. (15), 131–139 (1993).
  MedlineGoogle Scholar
• 3 Weiss RB, Donehower R, Wiernik P et al. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8(7), 1263–1268 (1990).
  Medline CASGoogle Scholar
• 4 Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235(1), 179–192 (2002). • The hurdles and challenges of the current marketed paclitaxel formulations are highlighted.
  Medline CASGoogle Scholar
• 5 Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37(13), 1590–1598 (2001). • The problems associated with the current solvent system employed for paclitaxel formulation are highlighted.
  Medline CASGoogle Scholar
• 6 Ghadi R, Dand N. BCS class IV drugs: highly notorious candidates for formulation development. J. Control. Rel. 248, 71–95 (2017).
  Medline CASGoogle Scholar
• 7 Li F, Li J, Wen X et al. Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: an in vitro study. Mater. Sci. Eng. C. 29(8), 2392–2397 (2009).
  CASGoogle Scholar
• 8 Kim J-H, Kim Y-S, Kim S et al. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Rel. 111(1), 228–234 (2006).
  Medline CASGoogle Scholar
• 9 Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Rel. 83(2), 273–286 (2002).
  Medline CASGoogle Scholar
• 10 Mu L, Feng S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol^®): PLGA nanoparticles containing vitamin E TPGS. J. Control. Rel. 86(1), 33–48 (2003).
  Medline CASGoogle Scholar
• 11 Danhier F, Lecouturier N, Vroman B et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control. Rel. 133(1), 11–17 (2009).
  Medline CASGoogle Scholar
• 12 Mu L, Feng S-S. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm. Res. 20(11), 1864–1872 (2003).
  Medline CASGoogle Scholar
• 13 Dong Y, Feng S-S. method poly (ethylene glycol)-poly (lactide)(MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25(14), 2843–2849 (2004).
  Medline CASGoogle Scholar
• 14 Kaul G, Amiji M. Long-circulating poly (ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm. Res. 19(7), 1061–1067 (2002).
  Medline CASGoogle Scholar
• 15 Tseng C-L, Wang T-W, Dong G-C et al. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28(27), 3996–4005 (2007).
  Medline CASGoogle Scholar
• 16 Swami R, Singh I, Jeengar MK, Naidu V, Khan W, Sistla R. Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting. Int. J. Pharm. 486(1–2), 287–296 (2015).
  Medline CASGoogle Scholar
• 17 Singh I, Swami R, Pooja D, Jeengar MK, Khan W, Sistla R. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug-delivery system for potential brain targeting. J. Drug Target. 24(3), 212–223 (2016).
  Medline CASGoogle Scholar
• 18 Tran PH-L, Tran TT-D, Vo TV, Vo CL-N, Lee B-J. Novel multifunctional biocompatible gelatin-oleic acid conjugate: self-assembled nanoparticles for drug delivery. J. Biomed. Nanotechnol. 9(8), 1416–1431 (2013). • The potential of hydrophobized gelatin conjugates to form self-assembled nanoparticles is highlighted.
  Medline CASGoogle Scholar
• 19 Tran PH-L, Tran TT-D, Lee B-J. Biodistribution and pharmacokinetics in rats and antitumor effect in various types of tumor-bearing mice of novel self-assembled gelatin-oleic acid nanoparticles containing paclitaxel. J. Biomed. Nanotechnol. 10(1), 154–165 (2014).
  Medline CASGoogle Scholar
• 20 Park C, Vo CL-N, Kang T, Oh E, Lee B-J. New method and characterization of self-assembled gelatin–oleic nanoparticles using a desolvation method via carbodiimide/N-hydroxysuccinimide (EDC/NHS) reaction. Eur. J. Pharm. Biopharm. 89, 365–373 (2015). • The various techniques employed for characterization of hydrophobized gelatin nanoparticles are highlighted.
  Medline CASGoogle Scholar
• 21 Shilpi D, Kushwah V, Agrawal AK, Jain S. Improved stability and enhanced oral bioavailability of atorvastatin-loaded stearic acid-modified gelatin nanoparticles. Pharm. Res. 34(7), 1505–1516 (2017). • The potential of hydrophobized gelatin nanoparticles for improving stability and oral bioavailability is showcased.
  Medline CASGoogle Scholar
• 22 Hemshekhar M, Sebastin Santhosh M, Kemparaju K, Girish KS. Emerging roles of anacardic acid and its derivatives: a pharmacological overview. Basic Clin. Pharmacol. Toxicol. 110(2), 122–132 (2012). •• The role and various pharmacological actions of anacardic acid (AA) are highlighted.
  Medline CASGoogle Scholar
• 23 Shelma R, Paul W, Sharma CP. Development and characterization of self-aggregated nanoparticles from anacardoylated chitosan as a carrier for insulin. Carbohydr. Polym. 80(1), 285–290 (2010).
  CASGoogle Scholar
• 24 Sung B, Pandey MK, Ahn KS et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-κB–regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-κBα kinase, leading to potentiation of apoptosis. Blood 111(10), 4880–4891 (2008).
  Medline CASGoogle Scholar
• 25 Schultz DJ, Wickramasinghe NS, Ivanova MM et al. Anacardic acid inhibits estrogen receptor α–DNA binding and reduces target gene transcription and breast cancer cell proliferation. Mol. Cancer Ther. 9(3), 594–605 (2010).
  Medline CASGoogle Scholar
• 26 Shilpa P, Kaveri K, Salimath BP. Anti-metastatic action of anacardic acid targets VEGF-induced signalling pathways in epithelial to mesenchymal transition. Drug Discov. Ther. 9(1), 53–65 (2015). • The potential of AA for targeting VEGF receptors is highlighted.
  Medline CASGoogle Scholar
• 27 Kushwah V, Katiyar SS, Dora CP et al. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management. Acta Biomater. 73, 424–436 (2018). •• The potential role of AA for targeting nuclear and perinuclear region of cancer cells is highlighted.
  Medline CASGoogle Scholar
• 28 Coester C, Langer K, Von Briesen H, Kreuter J. Gelatin nanoparticles by two step desolvation a new preparation method, surface modifications and cell uptake. J. Microencapsul. 17(2), 187–193 (2000).
  Medline CASGoogle Scholar
• 29 Jain S, Spandana G, Agrawal AK, Kushwah V, Thanki K. Enhanced antitumor efficacy and reduced toxicity of docetaxel-loaded estradiol-functionalized stealth polymeric nanoparticles. Mol. Pharm. 12(11), 3871–3884 (2015).
  Medline CASGoogle Scholar
• 30 Lai SK, Hida K, Man ST et al. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials 28(18), 2876–2884 (2007).
  Medline CASGoogle Scholar
• 31 Jain S, Heeralal B, Swami R, Swarnakar NK, Kushwah V. Improved oral bioavailability, therapeutic efficacy, and reduced toxicity of tamoxifen-loaded liquid crystalline nanoparticles. AAPS PharmSciTech 19(1), 460–469 (2018).
  Medline CASGoogle Scholar
• 32 Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials 33(28), 6758–6768 (2012).
  Medline CASGoogle Scholar
• 33 Lu Z, Yeh T-K, Tsai M, Au JL-S, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 10(22), 7677–7684 (2004).
  Medline CASGoogle Scholar
• 34 Shutava TG, Balkundi SS, Vangala P et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 3(7), 1877–1885 (2009).
  Medline CASGoogle Scholar
• 35 Caboni L, Lloyd DG. Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. Med. Res. Rev. 33(5), 1081–1118 (2013).
  Medline CASGoogle Scholar
• 36 Hsieh C-C, Hernández-Ledesma B, Ben O. Cell proliferation inhibitory and apoptosis-inducing properties of anacardic acid and lunasin in human breast cancer MDA-MB-231 cells. Food Chem. 125(2), 630–636 (2011).
  CASGoogle Scholar
• 37 Simons M. An inside view: VEGF receptor trafficking and signaling. Physiology 27(4), 213–222 (2012).
  CASGoogle Scholar